
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.
Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.
Combinations that incorporate IDO inhibitors, STAT-3 inhibitors, and anti-KIR monoclonal antibodies, are doubling and even tripling response rates in patients with head and neck cancer, says Cohen.






